AR053859A1 - Compuestos heterociclicos fusionados - Google Patents

Compuestos heterociclicos fusionados

Info

Publication number
AR053859A1
AR053859A1 ARP060101661A ARP060101661A AR053859A1 AR 053859 A1 AR053859 A1 AR 053859A1 AR P060101661 A ARP060101661 A AR P060101661A AR P060101661 A ARP060101661 A AR P060101661A AR 053859 A1 AR053859 A1 AR 053859A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
amino
methyl
benzimidazol
compound
Prior art date
Application number
ARP060101661A
Other languages
English (en)
Inventor
K Aso
M Gyoten
A C Gyorkos
C P Corrette
S Y Cho
S A Pratt
C S Siedem
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR053859A1 publication Critical patent/AR053859A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque está representado por la formula (1), en donde R1 es un hidrocarbilo opcionalmente sustituido, un grupo heterocíclico enlazado a C opcionalmente sustituido, un grupo heteroarilo enlazado a N opcionalmente sustituido, o un acilo, con la condicion que sean excluidos metilo, y trifluorometilo; R2 es un hidrocarbilo cíclico opcionalmente sustituido o un grupo heterocíclico opcionalmente sustituido, con la condicion que sea excluido 2-[2- (1,1-dimetiletil)feniloxi]-3-piridinilo; X es oxígeno, azufre o -NR3- (en donde R3 es un hidrogeno, es un hidrocarbilo opcionalmente sustituido o un acilo); Y1, Y2 e Y3 cada uno es un carbono o un nitrogeno opcionalmente sustituido, con la condicion que uno o menos de Y1, Y2 e Y3 sea nitrogeno; y Z es un enlace, -CO-, oxígeno, azufre, -SO-, -SO2-, -NR4-, -NR4-alk-, -CONR4-, o -NR4CO (en donde el alk es un alquileno C1-4 opcionalmente sustituido y R4 es un hidrogeno, un hidrocarbilo opcionalmente sustituido o un acilo); con la condicion que: i) el compuesto en donde X es -NH-, y R2 sea un anillo de tiofeno opcionalmente sustituido; ii) el compuesto en donde R1 es ciano, Y3 es carbono que sustituido con metilo sustituido con tres sustituyentes uno de los cuales es acilo y los otros dos pueden formar un anillo; iii) a) 6-amino-2-[2,6-diclorofenil)amino]-1-metil-1H-bencimidazol-7-carbonitrilo; b) 6-amino-2-[(2,6-diclorofenil)amino]-1-metil-1H-bencimidazol-7-carboxamida; y c) 6-{[(acilamino)carbonotioil]amino}-2-[(2,6-diclorofenil)amino-1-metil-1H-bencimidazol-7-carboxamida; iv) 4-({2-[4-clorofenil)amino]-1,7-dimetil-1H-bencimidazol-5-il}oxi)-N-metilpiridin-2-carboxamida; v) el compuesto en donde R3 es heteroarilmetilo sustituido, R2 e 4-piperidinilo que lleva un sustituyente en la posicion 1; vi) el compuesto en donde R2 es 8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-en-7-ilo sustituido; y vii) 7-etil-1-metil-N-[4-(trifluorometoxi)fenil-5- (trifluormetil)-1H-bencimidazol-1-amina y 7-etenil-1-metil-N-[4-(trifluorometoxi)fenil]-5-(trifluorometil)-1H-bencimidazol-2-amina; son excluidas; o una sal del mismo.
ARP060101661A 2005-04-27 2006-04-26 Compuestos heterociclicos fusionados AR053859A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67511305P 2005-04-27 2005-04-27
US74210105P 2005-12-02 2005-12-02

Publications (1)

Publication Number Publication Date
AR053859A1 true AR053859A1 (es) 2007-05-23

Family

ID=37215421

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101661A AR053859A1 (es) 2005-04-27 2006-04-26 Compuestos heterociclicos fusionados

Country Status (19)

Country Link
US (1) US8163935B2 (es)
EP (1) EP1874736A4 (es)
JP (1) JP5061097B2 (es)
KR (1) KR101368037B1 (es)
AR (1) AR053859A1 (es)
AU (1) AU2006241210B2 (es)
BR (1) BRPI0610150A2 (es)
CA (1) CA2605453A1 (es)
CR (1) CR9421A (es)
GE (1) GEP20104962B (es)
IL (1) IL186407A (es)
MA (1) MA29486B1 (es)
MX (1) MX2007013154A (es)
NO (1) NO20075936L (es)
NZ (1) NZ562235A (es)
PE (1) PE20061377A1 (es)
RU (1) RU2408586C2 (es)
TW (1) TWI370820B (es)
WO (1) WO2006116412A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101193892A (zh) 2005-06-14 2008-06-04 先灵公司 大环杂环天冬氨酰基蛋白酶抑制剂
EP2088861A4 (en) * 2006-10-25 2010-07-07 Takeda Pharmaceutical BENZIMIDAZOLE COMPOUNDS
US8039500B2 (en) 2006-12-29 2011-10-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP2240485B1 (en) * 2008-01-22 2014-10-15 Takeda Pharmaceutical Company Limited Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
JP2011530483A (ja) * 2008-08-12 2011-12-22 武田薬品工業株式会社 アミド化合物
WO2010032461A1 (ja) * 2008-09-17 2010-03-25 武田薬品工業株式会社 含窒素縮合環化合物
AU2009296820B2 (en) 2008-09-26 2014-03-20 Merck Sharp & Dohme Llc Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
EP2352374B1 (en) 2008-10-29 2014-09-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2518054A1 (en) * 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
JP5806735B2 (ja) 2010-07-02 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ抗ウイルス化合物としての２−キノリニル−酢酸誘導体
AP2015008931A0 (en) 2011-04-21 2015-12-31 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
HUE026671T2 (en) 2011-08-18 2016-07-28 Nippon Shinyaku Co Ltd Heterocyclic derivatives as microsomal prostaglandin E synthetase inhibitors (mPGEs)
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
EP3096756B1 (en) 2014-01-21 2024-06-12 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
EP3195865A1 (de) 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
BR112018067628A2 (pt) 2016-03-09 2018-12-26 Nippon Soda Co., Ltd. composto de piridina, fungicida agrícola e hortícola, agente de controle de organismo nocivo, agente inseticida ou acaricida, e, agente de controle de ectoparasita
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
RU2743170C2 (ru) 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
US20190125736A1 (en) 2016-06-01 2019-05-02 Bayer Pharma Aktiengesellschaft Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
US10765116B2 (en) 2016-11-23 2020-09-08 Bayer Cropscience Aktiengesellschaft 2-[3-(alkylsulfonyl)-2H-indazol-2-yl]-3H-imidazo[4,5-B]pyridine derivatives and similar compounds as pesticides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
WO1998005327A1 (en) * 1996-08-05 1998-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted aromatic compounds
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6376664B1 (en) * 1999-03-17 2002-04-23 The Ohio State University Cyclic bis-benzimidazole ligands and metal complexes thereof
RS50340B (sr) 1999-06-23 2009-11-10 Sanofi-Aventis Deutschland Gmbh., Supstituisani benzimidazoli
CZ20014574A3 (cs) 1999-06-28 2002-05-15 Janssen Pharmaceutica N. V. Inhibitory replikace respiračně syncyciálního viru
WO2001021615A1 (en) * 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
ATE277044T1 (de) 1999-10-06 2004-10-15 Boehringer Ingelheim Pharma Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
KR100571161B1 (ko) 2000-06-21 2006-04-17 에프. 호프만-라 로슈 아게 벤조티아졸 유도체
JP5000068B2 (ja) 2000-08-11 2012-08-15 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド チロシンキナーゼのインヒビターとして有用な複素環化合物
DE10060292A1 (de) 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament
US20020146469A1 (en) 2000-12-20 2002-10-10 Benjamin Wiegand Methods for reducing chronic stress in mammals
JP4152750B2 (ja) * 2001-02-05 2008-09-17 ディーエスエム アイピー アセッツ ビー．ブイ． 新規な２−ベンゾオキサゾリルベンゼン誘導体およびｕｖ遮断剤としてのそれらの使用
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
US6734179B2 (en) 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
GB0203045D0 (en) 2002-02-08 2002-03-27 Johnson & Johnson Consumer Method of afefecting sleep and sleep-related behaviours
US7071216B2 (en) 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
MXPA05003948A (es) * 2002-10-17 2005-06-17 Amgen Inc Derivados de bencimidazol y su uso como ligandos de receptor vaniloide.
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
EP1625115A1 (en) 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Substituted pyrimidine derivatives
US20040242560A1 (en) 2003-05-22 2004-12-02 Aventis Pharma Deutschland Gmbh Process for synthesizing heterocyclic compounds
EP1646614A4 (en) 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
US20050042212A1 (en) 2003-07-24 2005-02-24 Nanda Steven A. Method of reducing CRF receptor mRNA
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE10349587A1 (de) 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
EP1677791A4 (en) * 2003-10-31 2007-08-15 Takeda Pharmaceutical NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS
AR046959A1 (es) 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
RU2332414C2 (ru) 2003-12-18 2008-08-27 Тиботек Фармасьютикалз Лтд. Производные аминобензимидазолов в качестве ингибиторов репликации респираторного синцитиального вируса
DE602004031776D1 (de) 2003-12-18 2011-04-21 Tibotec Pharm Ltd Piperidinamino-benzimidazol-derivate al respiratorisches syncytialvirus replikation inhibitoren
CA2547785A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
EP1716136A1 (en) 2004-02-11 2006-11-02 Ulkar Kimya Sanayii Ve Ticaret A.S. Pyridine benzimidazole sulfoxides of high purity
US7429608B2 (en) * 2005-01-20 2008-09-30 Amgen Inc. Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments
EP2457901A1 (en) 2005-03-14 2012-05-30 High Point Pharmaceuticals, LLC Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
WO2008013270A1 (en) 2006-07-28 2008-01-31 Ono Pharmaceutical Co., Ltd. Method for diagnosis of neuropsychiatric disease
US8039500B2 (en) * 2006-12-29 2011-10-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP2240485B1 (en) * 2008-01-22 2014-10-15 Takeda Pharmaceutical Company Limited Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
JP2011530483A (ja) * 2008-08-12 2011-12-22 武田薬品工業株式会社 アミド化合物

Also Published As

Publication number Publication date
BRPI0610150A2 (pt) 2012-09-25
IL186407A0 (en) 2008-01-20
WO2006116412A8 (en) 2007-03-01
US20090312383A1 (en) 2009-12-17
KR20080000625A (ko) 2008-01-02
AU2006241210B2 (en) 2011-11-17
TW200716639A (en) 2007-05-01
JP5061097B2 (ja) 2012-10-31
CR9421A (es) 2007-12-12
RU2408586C2 (ru) 2011-01-10
RU2007143966A (ru) 2009-06-10
IL186407A (en) 2014-04-30
US8163935B2 (en) 2012-04-24
CA2605453A1 (en) 2006-11-02
WO2006116412A3 (en) 2007-06-28
NZ562235A (en) 2010-03-26
NO20075936L (no) 2007-11-19
PE20061377A1 (es) 2007-01-18
MX2007013154A (es) 2008-01-21
TWI370820B (en) 2012-08-21
EP1874736A2 (en) 2008-01-09
JP2008539247A (ja) 2008-11-13
AU2006241210A1 (en) 2006-11-02
KR101368037B1 (ko) 2014-02-26
GEP20104962B (en) 2010-04-26
WO2006116412A2 (en) 2006-11-02
MA29486B1 (fr) 2008-05-02
EP1874736A4 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
AR053859A1 (es) Compuestos heterociclicos fusionados
AR063458A1 (es) Derivados de piridina inhibidores de 11beta hsd1
AR061817A1 (es) Inhibidores de la replicacion del virus de la hepatitis c
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20091492A1 (es) Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
PE20120081A1 (es) Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20090188A1 (es) Compuestos heterociclicos como moduladores de la senda de hedgehog
AR055144A1 (es) Inhibidor de secrecion acida
CO5080792A1 (es) Heterociclos biciclicos disustituidos, su preparacion y su empleo como medicamentos
PE20030200A1 (es) Bencimidazol como inhibidores de las map quinasas
PE20110303A1 (es) Derivados de heteroaril acetamidas como activadores de glucoquinasa
IN2012DN00709A (es)
PE20090183A1 (es) Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5
PE20120320A1 (es) Pirazinilpirazoles
PE20121157A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
PE20041078A1 (es) Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh)
PE20090949A1 (es) Compuesto heterociclico y composicion farmaceutica del mismo
TW200738620A (en) Fluoroalkenyl derivatives as insecticides and nematicides
PE20081375A1 (es) Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5
AR062258A1 (es) Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv
PE20110299A1 (es) Nuevos derivados de acilaminobenzamida
AR079550A1 (es) Derivados de pirazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure